News

Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath.

Autoscribe Informatics is demonstrating the remote access capabilities of the Matrix Gemini Laboratory Information Management System (LIMS) at Lab Innovations.

Novartis have announced that the European Commission has approved Revolade® (eltrombopag) for the treatment of adults with severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant.

Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.

Agena Bioscience has announced the establishment of a subsidiary in Shanghai, a commercial and financial hub from which many biotech and life science firms serve the growing number of genomic testing laboratories in mainland China.

The company have announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.

Novartis have announced that the European Commission has approved the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Researchers seek to better understand genomic basis of disease, provide tailored care to patients.

Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.